Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma

Molecular Carcinogenesis

Volumn 52, Issue 3, 2013, Pages 229-236

  Wang, Cheng ^a,b   Liu, Xiqiang ^a,b   Chen, Zujian ^a   Huang, Hongzhang ^b   Jin, Yi ^a   Kolokythas, Antonia ^a   Wang, Anxun ^a,b   Dai, Yang ^a,c   Wong, David T W ^d   Zhou, Xiaofeng ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c University of Illinois at Chicago   (United States)

^d UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

E cadherin; EZH2; Metastasis; Prognosis; Squamous cell carcinoma

Indexed keywords

TRANSCRIPTION FACTOR EZH2; UVOMORULIN;

ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; METASTASIS; METASTASIS INHIBITION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TONGUE CARCINOMA;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; TONGUE NEOPLASMS;

EID: 84873273556     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21848     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. A Cancer J Clin 2010; 60: 277-300.
2. Franceschi D, Gupta R, Spiro RH, Shah JP. Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 1993; 166: 360-365.
3. Lydiatt DD, Robbins KT, Byers RM, Wolf PF. Treatment of stage I and II oral tongue cancer. Head Neck 1993; 15: 308-312.
4. Yuen AP, Lam KY, Chan AC, et al. Clinicopathological analysis of elective neck dissection for N0 neck of early oral tongue carcinoma. Am J Surg 1999; 177: 90-92.
5. Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 2005; 115: 629-639.
6. Teichgraeber JF, Clairmont AA. The incidence of occult metastases for cancer of the oral tongue and floor of the mouth: Treatment rationale. Head Neck Surg 1984; 7: 15-21.
7. Cunningham MJ, Johnson JT, Myers EN, Schramm VL, Jr, Thearle PB. Cervical lymph node metastasis after local excision of early squamous cell carcinoma of the oral cavity. Am J Surg 1986; 152: 361-366.
8. Ho CM, Lam KH, Wei WI, Lau SK, Lam LK. Occult lymph node metastasis in small oral tongue cancers. Head Neck 1992; 14: 359-363.
9. Rao ZY, Cai MY, Yang GF, et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010; 31: 1576-1583.
10. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
11. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611.
12. Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003; 5: 481-488.
13. Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92: 1754-1758.
14. Kidani K, Osaki M, Tamura T, et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009; 45: 39-46.
15. Wang A, Liu X, Sheng S, et al. Dysregulation of heat shock protein 27 expression in oral tongue squamous cell carcinoma. BMC Cancer 2009; 9: 167.
16. Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett 2009; 286: 217-222.
17. Liu X, Yu J, Jiang L, et al. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics 2009; 6: 131-139.
18. Jiang L, Liu X, Kolokythas A, et al. Down-regulation of the Rho GTPase signaling pathway is involved in the microRNA-138 mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010; 127: 505-512.
19. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 7274-7284.
20. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846-856.
21. Vleminckx K, Vakaet L, Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-119.
22. Birchmeier W, Behrens J. Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994; 1198: 11-26.
23. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001; 105: 391-402.
24. Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 2008; 99: 738-746.
25. Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011; 26: 19-27.
26. Cao W, Feng Z, Cui Z, et al. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer 2011; Epub ahead of print: Oct 11: DOI: 10.1002/cncr.26575.